Drug distribution between blood and brain as a determinant of antipsychotic drug effects
暂无分享,去创建一个
[1] D. Klein. Diagnosis and Drug Treatment of Psychiatric Disorders , 1969, British Journal of Psychiatry.
[2] J. Meek,et al. Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. , 1983, Clinical chemistry.
[3] J. Barchas,et al. 19F magnetic resonance imaging and spectroscopy of a fluorinated neuroleptic ligand: In vivo and in vitro studies , 1988, Psychiatry Research.
[4] B. Cohen,et al. Clinical use of the radioreceptor assay for neuroleptics , 1980, Psychiatry Research.
[5] Bruno Giros,et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.
[6] A. Stoll,et al. Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection. , 1984, Journal of chromatography.
[7] Susan R. George,et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.
[8] R. Goldney,et al. Cohort analysis of suicide rates in Australia. , 1983, Archives of general psychiatry.
[9] W. Stigelman,et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .
[10] H. Lôo,et al. Brain distribution and kinetics of 11C-chlorpromazine in schizophrenics: Positron emission tomography studies , 1979, Psychiatry Research.
[11] C. Karson,et al. Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy , 1991, Biological Psychiatry.
[12] Philip Seeman,et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.
[13] J. Korf,et al. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients , 1991, Biological Psychiatry.
[14] G. Sedvall,et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. , 1988, Archives of general psychiatry.
[15] G. Huber. Advances in Schizophrenia Research , 1990 .
[16] Martin H. Teicher,et al. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. , 1988, Archives of general psychiatry.
[17] P. Seeman,et al. Anti-schizophrenic drugs--membrane receptor sites of action. , 1977, Biochemical pharmacology.
[18] J. Leysen,et al. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. , 1979, Biochemical pharmacology.
[19] S. Peroutka,et al. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. , 1980, The American journal of psychiatry.
[20] B. Cohen,et al. Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites , 1979, Psychiatry Research.
[21] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[22] Bruce M. Cohen,et al. Blood to brain distribution of neuroleptics , 1987, Psychiatry Research.
[23] E. Richelson,et al. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. , 1984, European journal of pharmacology.
[24] P. Seeman,et al. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[25] B. Cohen,et al. Persistence of haloperidol in the brain. , 1988, Archives of general psychiatry.
[26] R. Cluxton,et al. Astemizole: A Long-Acting, Nonsedating Antihistamine , 1987, Drug intelligence & clinical pharmacy.
[27] T. Craig,et al. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. , 1987, The American journal of psychiatry.
[28] B. Cohen,et al. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. , 1986, Life sciences.
[29] N. W. Winkelman. Chlorpromazine in the treatment of neuropsychiatric disorders. , 1954, Journal of the American Medical Association.
[30] R. Baldessarini,et al. Dissimilar dosing with high-potency and low-potency neuroleptics. , 1984, The American journal of psychiatry.
[31] E. Sorkin,et al. Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. , 1985 .
[32] S H Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.